Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer
- PMID: 39442954
- PMCID: PMC11648064
- DOI: 10.1002/pros.24815
Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer
Abstract
Backgrounds: SWI/SNF complexes represent a family of multi-subunit chromatin remodelers that are affected by alterations in >20% of human tumors. While mutations of SWI/SNF genes are relatively uncommon in prostate cancer (PCa), the literature suggests that deregulation of various subunits plays a role in prostate tumorigenesis. To assess SWI/SNF functions in a clinical context, we studied the mutually exclusive, paralogue accessory subunits SMARCD1, SMARCD2, and SMARCD3 that are included in every known complex and are sought to confer specificity.
Methods: Performing immunohistochemistry (IHC), the protein levels of the SMARCD family members were measured using a tissue microarray (TMA) comprising malignant samples and matching healthy tissue of non-metastatic PCa patients (n = 168). Moreover, IHC was performed in castration-resistant tumors (n = 9) and lymph node metastases (n = 22). To assess their potential role as molecular biomarkers, SMARCD1 and SMARCD3 protein levels were correlated with clinical parameters such as T stage, Gleason score, biochemical recurrence, and progression-free survival.
Results: SMARCD1 protein levels in non-metastatic primary tumors, lymph node metastases, and castration-resistant samples were significantly higher than in benign tissues. Likewise, SMARCD3 protein expression was elevated in tumor tissue and especially lymph node metastases compared to benign samples. While SMARCD1 levels in primary tumors did not exhibit significant associations with any of the tested clinical parameters, SMARCD3 exhibited an inverse correlation with pre-operative PSA levels. Moreover, low SMARCD3 expression was associated with progression to metastasis.
Conclusions: In congruence with previous literature, our results implicate that both SMARCD1 and SMARCD3 may exhibit relevant functions in the context of prostate tumorigenesis. Moreover, our approach suggests a potential role of SMARCD3 as a novel prognostic marker in clinically non-metastatic PCa.
Keywords: SMARCD1; SMARCD3; SWI/SNF complex; prognostic marker; prostate cancer.
© 2024 The Author(s). The Prostate published by Wiley Periodicals LLC.
Conflict of interest statement
All authors declare no conflict of interest.
Figures


Similar articles
-
The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer.Cells. 2022 Dec 28;12(1):124. doi: 10.3390/cells12010124. Cells. 2022. PMID: 36611918 Free PMC article.
-
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer.Breast Cancer Res Treat. 2021 Feb;185(3):601-614. doi: 10.1007/s10549-020-05997-5. Epub 2020 Nov 12. Breast Cancer Res Treat. 2021. PMID: 33180234 Free PMC article.
-
Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway.Clin Sci (Lond). 2020 Jun 26;134(12):1457-1472. doi: 10.1042/CS20200244. Clin Sci (Lond). 2020. PMID: 32514535
-
SWI/SNF chromatin remodeling and human malignancies.Annu Rev Pathol. 2015;10:145-71. doi: 10.1146/annurev-pathol-012414-040445. Epub 2014 Oct 27. Annu Rev Pathol. 2015. PMID: 25387058 Review.
-
BAFfling pathologies: Alterations of BAF complexes in cancer.Cancer Lett. 2018 Apr 10;419:266-279. doi: 10.1016/j.canlet.2018.01.046. Epub 2018 Jan 31. Cancer Lett. 2018. PMID: 29374542 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous